Analysts at HSBC Maintained their Buy rating for Genus PLC (LON:GNS). The Target Price per Share Given is GBX 2700.00; Electromed (NYSEAMERICAN:ELMD) Shorts Down By 43.79%

Genus plc (LON:GNS) Logo

Electromed Inc (NYSEAMERICAN:ELMD) had a decrease of 43.79% in short interest. ELMD’s SI was 8,600 shares in March as released by FINRA. Its down 43.79% from 15,300 shares previously. With 16,000 avg volume, 1 days are for Electromed Inc (NYSEAMERICAN:ELMD)’s short sellers to cover ELMD’s short positions. The SI to Electromed Inc’s float is 0.14%. The stock decreased 2.14% or $0.12 during the last trading session, reaching $5.48. About 1,394 shares traded. Electromed, Inc. (NYSEAMERICAN:ELMD) has declined 6.36% since March 15, 2018 and is downtrending. It has underperformed by 10.73% the S&P500. Some Historical ELMD News: 26/04/2018 – Electromed, Inc. Announces Results of a Longitudinal Outcome-Based Study: Bronchiectasis Exacerbations Significantly Reduced; 23/05/2018 – Electromed, Inc. to Receive Refund for Medical Device Excise Taxes Paid; 08/05/2018 – Electromed 3Q Rev $7.09M; 08/05/2018 – Electromed 3Q EPS 4c; 26/04/2018 – Electromed, Inc. Announces Results of a Longitudinal Outcome-Based Study: Bronchiectasis Exacerbations Significantly Reduced with HFCWO Therapy; 19/04/2018 DJ Electromed Inc, Inst Holders, 1Q 2018 (ELMD); 26/04/2018 – ELMD: HFCWO STUDY HAD SIG. REDUCED BRONCHIECTASIS EXACERBATIONS

The financial company have set PT of GBX 2700.00 on Genus PLC (LON:GNS) shares. This is 10.75% from the last close price. In a report sent to investors on Friday morning, HSBC reiterated their Buy rating on shares of GNS.

Since February 15, 2019, it had 1 buying transaction, and 0 insider sales for $57,143 activity. Craney Stephen H. bought 10,000 shares worth $57,143.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products in the United States and internationally. The company has market cap of $45.95 million. The firm offers SmartVest airway clearance system that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to patients with compromised pulmonary function; and SmartVest SQL System that provides advanced generator programmability and an enhanced pause feature with save, lock, and restore functionality. It has a 24.91 P/E ratio. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers working in intensive care units; and Aerobika, an oscillating positive expiratory pressure device.

Investors sentiment increased to 5 in 2018 Q4. Its up 3.00, from 2 in 2018Q3. It increased, as 2 investors sold Electromed, Inc. shares while 1 reduced holdings. 2 funds opened positions while 13 raised stakes. 4.03 million shares or 119.06% more from 1.84 million shares in 2018Q3 were reported. 77,265 were reported by White Pine Llc. Dimensional Fund Advisors L P owns 179,506 shares or 0% of their US portfolio. Creative Planning reported 0% stake. Deutsche Bank & Trust Ag holds 0% or 16,320 shares. Carlson Cap Mgmt invested in 0.02% or 14,134 shares. Punch & Associates Inv Mgmt owns 40,715 shares. Acadian Asset Ltd Liability has invested 0% in Electromed, Inc. (NYSEAMERICAN:ELMD). Spark Management Lc reported 16,500 shares stake. Renaissance Technology Ltd Llc stated it has 72,820 shares. Gabelli Funds Ltd Co reported 95,267 shares or 0% of all its holdings. Vanguard Group accumulated 0% or 282,447 shares. Tocqueville Asset Ltd Partnership invested in 439,700 shares or 0.03% of the stock. Quantum Cap invested 0.37% of its portfolio in Electromed, Inc. (NYSEAMERICAN:ELMD). Panagora Asset Management invested in 0% or 6,653 shares. Bridgeway Capital Mgmt holds 301,538 shares or 0.02% of its portfolio.

More notable recent Electromed, Inc. (NYSEAMERICAN:ELMD) news were published by: Digitaljournal.com which released: “Electromed, Inc. To Participate in the Sidoti & Company Spring 2019 Conference – Press Release – Digital Journal” on March 14, 2019, also Businesswire.com with their article: “Electromed, Inc. Announces Fiscal 2019 Second Quarter Financial Results – Business Wire” published on February 12, 2019, Businesswire.com published: “Electromed, Inc. Schedules Release of Second Quarter Fiscal 2019 Financial Results and Conference Call – Business Wire” on January 30, 2019. More interesting news about Electromed, Inc. (NYSEAMERICAN:ELMD) were released by: Businesswire.com and their article: “Electromed, Inc. Schedules Release of First Quarter Fiscal 2019 Financial Results and Conference Call – Business Wire” published on October 31, 2018 as well as Businesswire.com‘s news article titled: “Electromed, Inc. Announces Fiscal 2019 First Quarter Financial Results – Business Wire” with publication date: November 13, 2018.

Among 2 analysts covering Genus PLC (LON:GNS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Genus PLC has GBX 2650 highest and GBX 2500 lowest target. GBX 2565’s average target is 4.95% above currents GBX 2444 stock price. Genus PLC had 18 analyst reports since October 2, 2018 according to SRatingsIntel. The stock of Genus plc (LON:GNS) has “Hold” rating given on Thursday, November 15 by Peel Hunt. On Thursday, November 1 the stock rating was maintained by Peel Hunt with “Hold”. The stock of Genus plc (LON:GNS) earned “Hold” rating by Peel Hunt on Monday, November 19. On Monday, January 7 the stock rating was maintained by Peel Hunt with “Buy”. The company was upgraded on Tuesday, March 5 by Liberum Capital. As per Tuesday, October 2, the company rating was maintained by Peel Hunt. The stock of Genus plc (LON:GNS) earned “Hold” rating by Peel Hunt on Thursday, December 6. On Thursday, December 6 the stock rating was upgraded by Kepler Cheuvreux to “Buy”. The firm earned “Hold” rating on Friday, October 12 by Peel Hunt. The stock of Genus plc (LON:GNS) has “Buy” rating given on Wednesday, February 6 by Peel Hunt.

Genus plc, together with its subsidiaries, engages in the application of quantitative genetics and biotechnology for animal breeding in the porcine and bovine sectors. The company has market cap of 1.58 billion GBP. It operates through three divisions: Genus PIC, Genus ABS, and Research and Development. It currently has negative earnings. The firm sells sows, boars, and semen under the PIC name to breed pigs with various characteristics for pork production.

Electromed, Inc. (NYSEAMERICAN:ELMD) Institutional Positions Chart